الفهرس 
EPIDEMIOLOGY AND ETIOLOGICAL FACTORSOnly 14 pages are availabe for public view
 |  | from | 281 |  |  |
| | | from | 281 | | |
Abstract
Major studies shown a significant DFS and OS advantage for different schedules of A.I treatment, including upfront AIs or sequential use of tamoxifen and AIs, have been shown to improve disease-free survival and overall survival compared with tamoxifen alone. The benefit of AIs on breast cancer recurrence and mortality far outweigh the risks of adverse events, and this should be taken into account when considering treatment options for patients. Nevertheless, cardiovascular events reported in clinical trials with AIs raise potential concerns that suggest the need for additional follow-up and studies.
Our cross sectional study that assessed cardiotoxicity for adjuvant and metastatic breast cancer patients at Ain-Shams university clinical oncology department in the interval from August 2016 to June 2017, a total of 123 hormone receptor positive postmenopausal women were treated with Aromatase Inhibitors (AIs) showed evidence of cardiotoxicity by ECHO in 71 patients (57.7% of study population) (P value=0.016). However, it was not detected by blood pressure measurement, lipid profile, ECG. So, ECHO represents an important tool for screening cardiotoxicity that seems to be associated with use of A.I in postmenopausal patients. With the goal of early detection of cancer treatment–related cardiac toxicity, leading to early treatment that results in better survival outcomes.